Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Post-treatment with Meloxicam Attenuates MPP+-Induced Neurotoxicity via PI3K/Akt-Dependent Maintenance of Mcl-1.

Created on 26 Oct 2026

Authors

Yasuhiro Matsuura, Takayuki Manabe, Tomoko Ohkubo, Masaya Kanda, Kuninori Iwayama, Naoya Kamiyama, Masayuki Chuma, Yoshikazu Tasaki

Published in

Biological & pharmaceutical bulletin. Volume 49. Issue 10. Pages 1703-1708.

Abstract

Parkinson's disease (PD) is a neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons in the nigrostriatal pathway. Current treatments for PD primarily provide symptomatic relief through dopamine replacement; however, no neuroprotective drugs are currently clinically available. Our previous work demonstrated that meloxicam (MLX) protects against 1-methyl-4-phenylpyridinium (MPP+)-induced neurotoxicity in human neuroblastoma SH-SY5Y cells via the phosphatidylinositol 3-kinase (PI3K)/Akt pathway, independent of cyclooxygenase inhibition. However, the downstream mechanisms remain unclear. In this study, we examined which anti-apoptotic B-cell lymphoma-2 (Bcl-2) family proteins, including Bcl-2, Bcl-xL, and myeloid cell leukemia 1 (Mcl-1), contribute to MLX-mediated neuroprotection. We also evaluated whether post-treatment with MLX can rescue MPP+-induced neurotoxicity, considering its potential clinical applicability. Cell viability assays and Western blotting were performed to assess neuronal survival and protein expression. Our results show that post-treatment with MLX restored neuronal viability after MPP+ exposure through the PI3K/Akt/Mcl-1 pathway, indicating that MLX can attenuate MPP+-induced apoptotic progression even when administered at delayed time points. These findings elucidate the molecular basis of MLX-mediated neuroprotection and support the potential therapeutic repurposing of MLX as a neuroprotective agent for PD.

PMID:
42927891
Bibliographic data and abstract were imported from PubMed on 26 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 24
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement